{{Infobox drug
| drug_name         =
| INN               =
| type              =<!-- empty -->
| IUPAC_name        = 
| image             = Semaglutide.svg
| width             = 300px
| alt               = 
| caption           =
<!-- Clinical data -->
| pronounce         =
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A/B1/B2/B3/C/D/X -->
| pregnancy_AU_comment = 
| pregnancy_US      = <!-- A/B/C/D/X/N -->
| pregnancy_category= 
| routes_of_administration = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_DE = <!-- Anlage I, II, III -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status      = Investigational
<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       =
| onset             = 
| elimination_half-life = 
| duration_of_action =
| excretion         = 
<!-- Identifiers -->
| CAS_number        = 910463-68-2
| class             = 
| ATCvet            = 
| ATC_prefix        = <!-- 'none' if uncategorised -->
| ATC_suffix        = 
| PubChem           = 56843331
| DrugBank          = 
| UNII = 53AXN4NNHX
<!-- Chemical and physical data -->
| C=187|H=291|N=45|O=59
| StdInChIKey = DLSWIYLPEUIQAV-CCUURXOWSA-N
}}

'''Semaglutide''' ([[United States Adopted Name|USAN]]) is a pharmaceutical drug in [[drug development|development]] by [[Novo Nordisk]] for the treatment of [[type 2 diabetes]].<ref>{{Cite web | url = https://www.drugs.com/history/semaglutide.html | title = Semaglutide Approval Status | publisher = [[drugs.com]]}}</ref><ref>{{cite press release | url = http://press.novonordisk-us.com/2016-12-05-Novo-Nordisk-Files-for-Regulatory-Approval-of-Once-Weekly-Semaglutide-with-the-FDA-for-the-Treatment-of-Type-2-Diabetes | title = Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide with the FDA for the Treatment of Type 2 Diabetes | date = December 5, 2016 | publisher = Novo Nordisk}}</ref>

==Mechanism of action==
Semaglutide is a [[glucagon-like peptide-1]] (GLP-1) analog and functions as a [[glucagon-like peptide-1 receptor agonist|GLP-1 agonist]].<ref>{{Cite journal | doi = 10.1056/NEJMoa1607141| pmid = 27633186| title = Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes| journal = New England Journal of Medicine| volume = 375| issue = 19| pages = 1834| year = 2016| last1 = Marso| first1 = Steven P.| last2 = Bain| first2 = Stephen C.| last3 = Consoli| first3 = Agostino| last4 = Eliaschewitz| first4 = Freddy G.| last5 = Jódar| first5 = Esteban| last6 = Leiter| first6 = Lawrence A.| last7 = Lingvay| first7 = Ildiko| last8 = Rosenstock| first8 = Julio| last9 = Seufert| first9 = Jochen| last10 = Warren| first10 = Mark L.| last11 = Woo| first11 = Vincent| last12 = Hansen| first12 = Oluf| last13 = Holst| first13 = Anders G.| last14 = Pettersson| first14 = Jonas| last15 = Vilsbøll| first15 = Tina}}</ref>

==References==
{{reflist}}


{{Signaling peptide/protein receptor modulators}}

[[Category:Glucagon-like peptide-1 agonists]]
[[Category:Peptides]]